Dr. Radich On Treatment Discontinuation In Cml Off Trial

Dr. Radich on Treatment Discontinuation in CML Off Trial

Dr. Radich on Compliance to NCCN Guidelines in CML

Dr. Jerald P. Radich on Treatment Considerations with Generic Imatinib in CML

Dr. Shah on TKI Treatment Discontinuation in CML

Dr. Seet on Aspects of Treatment Discontinuation in CML

Dr. Jerald Radich on Impact of Generic Imatinib in CML

Relapse After CML Treatment Discontinuation

Discontinuation of Treatment With TKIs in Chronic Myelogenous Leukemia

Dr. Michael Mauro on Treatment Discontinuation for CML

Dr. Sweet Discusses TKI Discontinuation in CML

Treatment-free remission after second-generation TKI treatment in CML

VJHemOnc – Video Journal of Hematology & HemOnc

Myeloid Leukemias: A Model for Molecular Diagnostics and Targeted Cancer Therapy - Jerald Radich, MD

Dr. Biran Discusses Treatment Discontinuation in Myeloma

Dr. Radich on the Utility of MRD in Hematologic Malignancies

Recommendations for treatment discontinuation in CML

VJHemOnc – Video Journal of Hematology & HemOnc

Chronic Myeloid Leukemia Treatment Discontinuation

Nilotinib Benefits Relapsed Patients With CML After Treatment Discontinuation

Targeted Oncology

Treatment-Free Remission in CML

Treatment-Free Remission & Toxicities of Discontinuing CML Therapy

Targeted Oncology

The NILSt and D-STOP Trials in CML